bevacizumab
roche
['beva']
nice commentary by attempting to explain os benefit without pfs improvement. nice algorithm proposed. note that os curves cross at 2 years meaning pts with bad prognosis will benefit equally or better by beva. #asco22. 
??????????? ??? ????????. Passionate and perfectionist. Med Onc with special love to Gyn Onc and prostate cancer.